Additional Study Information: The purpose of this study is to test the study drug ALKS 4230 to see how well the drug works on patients with advanced cutaneous melanoma or subjects with advanced mucosal melanoma and have received prior treatment with an anti-programmed death-ligand 1 (anti-PD-L1) therapy, and your cancer has spread. This study will explore how well the drug works on your disease and body; also explore potential biomarkers by examining your blood and tissue for genes and proteins that can help identify and/or predict whether therapy would benefit someone or not.